YHR071C-A Antibody

What is YHR071C-A and why is it significant for antibody development?

YHR071C-A is a yeast gene encoding a protein that serves as an important model for studying fundamental biological processes. Antibodies targeting this protein are valuable research tools for investigating protein function, localization, and interaction studies. The protein's conserved structure across species makes it particularly useful for comparative studies. Methodologically, researchers typically verify antibody specificity through multiple validation techniques including Western blotting, immunoprecipitation, and immunofluorescence against both wild-type samples and YHR071C-A knockout controls .

How should researchers validate the specificity of a YHR071C-A antibody?

Validation of YHR071C-A antibodies requires a multi-technique approach:

• Western blot analysis - Confirm single band at expected molecular weight in wild-type samples, with absence in knockout controls

• Immunoprecipitation followed by mass spectrometry to confirm target protein identity

• Immunofluorescence microscopy to verify expected subcellular localization

• ELISA testing against recombinant YHR071C-A protein and related family members to assess cross-reactivity

• Flow cytometry for quantitative binding assessment

Similar to validation approaches used in antibody development platforms like REAP, proper YHR071C-A antibody validation should demonstrate specificity with minimal off-target binding across multiple assays .

What controls are essential when using YHR071C-A antibodies in experimental protocols?

A comprehensive control strategy should be implemented across experiments to ensure data reliability. When troubleshooting unexpected results, control experiments often reveal protocol optimization opportunities rather than antibody deficiencies .

How can researchers optimize immunoprecipitation protocols specifically for YHR071C-A?

Optimizing immunoprecipitation for YHR071C-A requires consideration of the protein's biochemical properties:

• Buffer selection: Use buffers containing 0.1-0.5% NP-40 or Triton X-100 for initial extraction while maintaining protein complex integrity.

• Cross-linking consideration: For transient interactions, implement reversible cross-linking with DSP (dithiobis[succinimidyl propionate]) at 0.5-2mM for 30 minutes.

• Antibody coupling: Covalently couple YHR071C-A antibodies to magnetic beads using NHS-ester chemistry to prevent antibody leaching and contamination.

• Washing stringency gradient: Implement sequential washes with increasing salt concentration (150mM to 500mM NaCl) to remove non-specific binders while preserving genuine interactions.

• Elution optimization: For native conditions, use competitive elution with excess antigen peptide; for higher yield, employ pH elution (glycine buffer, pH 2.5) with immediate neutralization.

This methodological approach mirrors techniques used for isolating antibody-antigen complexes in high-throughput screening platforms, adapted specifically for YHR071C-A research contexts .

What are the critical considerations when developing a high-affinity monoclonal antibody against YHR071C-A?

Developing high-affinity monoclonal antibodies against YHR071C-A requires:

• Antigen design strategy: Use multiple immunization approaches including:

  • Full-length recombinant protein for comprehensive epitope coverage

  • Peptide conjugates representing unique, accessible regions

  • DNA immunization to present native conformational epitopes

• Hybridoma screening hierarchy:

  • Primary screen: ELISA against immobilized antigen

  • Secondary screen: Western blot and IP functionality

  • Tertiary screen: Application-specific validation (IF, ChIP, functional blocking)

• Affinity maturation considerations: Implement directed evolution approaches including:

  • CDR-targeted mutagenesis libraries

  • Phage display selection under increasingly stringent conditions

  • Yeast surface display for quantitative binding assessment

• Epitope binning analysis: Categorize antibody candidates into distinct epitope bins to develop complementary antibody panels targeting different protein regions.

This systematic approach parallels advanced methodologies used in therapeutic antibody development, such as those employed for bispecific antibodies like YM101, adapted for research-grade reagent development .

How can researchers effectively troubleshoot non-specific binding issues with YHR071C-A antibodies?

When facing non-specific binding challenges:

• Systematic elimination approach:

  • Increase blocking agent concentration (5% BSA or 5% milk) and duration (overnight at 4°C)

  • Implement additional washing steps with increased detergent (0.1-0.5% Tween-20)

  • Add competing proteins (0.1-0.5% BSA) to antibody dilution buffer

  • Pre-adsorb antibody with similar proteins/extracts from null cells

• Cross-reactivity analysis:

  • Perform epitope mapping to identify potentially cross-reactive sequences

  • Test against protein family members to quantify cross-reactivity

  • Implement bioinformatic analysis to identify proteins with similar epitopes

• Buffer optimization matrix:

  Buffer Component	Test Range	Evaluation Metric
  Salt (NaCl)	150-500mM	Signal-to-noise ratio
  Detergent (Tween-20)	0.05-0.3%	Background reduction
  pH	6.8-8.0	Specific binding retention
  Blocking protein	BSA vs. Casein vs. Gelatin	Non-specific binding reduction

• Monoclonal vs. polyclonal reassessment: Consider switching antibody format based on application requirements and specificity challenges.

These troubleshooting approaches draw from techniques used in high-throughput antibody validation platforms like REAP, which emphasize rigorous specificity assessment across multiple experimental conditions .

What are the optimal conditions for using YHR071C-A antibodies in chromatin immunoprecipitation (ChIP) experiments?

For effective ChIP experiments with YHR071C-A antibodies:

• Cross-linking optimization:

  • For protein-DNA interactions: 1% formaldehyde for 10 minutes at room temperature

  • For protein-protein-DNA complexes: Implement dual cross-linking with 1.5mM EGS (ethylene glycol bis[succinimidyl succinate]) for 30 minutes followed by formaldehyde

• Sonication parameters:

  • Target fragment size: 200-500bp for standard ChIP, 100-300bp for ChIP-seq

  • Sonication buffer: Include protease inhibitors, 1% Triton X-100, 0.1% sodium deoxycholate

• Antibody incubation:

  • Concentration: 2-5μg antibody per ChIP reaction

  • Duration: Overnight at 4°C with rotation

  • Pre-clearing: Implement with protein A/G beads for 2 hours before antibody addition

• Washing stringency gradient:

  • Low salt wash (150mM NaCl)

  • High salt wash (500mM NaCl)

  • LiCl wash (250mM LiCl)

  • TE buffer wash

• Controls integration:

  • Input control: 5-10% pre-immunoprecipitation chromatin

  • IgG control: Matched isotype antibody

  • Positive control regions: Known binding sites for validation

This methodological approach is similar to validation techniques used for functional antibodies characterized through high-throughput screening platforms .

How can YHR071C-A antibodies be employed in multi-color flow cytometry panels?

For optimal integration of YHR071C-A antibodies in multi-color flow cytometry:

• Panel design considerations:

  • Assign YHR071C-A antibody to appropriate fluorophore based on expression level (brighter fluorophores for lower expression)

  • Position in spectral spillover matrix to minimize compensation requirements

  • Consider intracellular vs. surface staining requirements

• Titration optimization:

  • Perform antibody titration series (0.1-10μg/ml)

  • Calculate staining index for each concentration: (MFI positive - MFI negative) / (2 × SD of negative)

  • Select concentration with highest staining index, not necessarily strongest signal

• Protocol optimization:

  • Fixation impact assessment: Test multiple fixatives (paraformaldehyde vs. methanol) for epitope preservation

  • Permeabilization agent selection: Compare saponin (0.1-0.5%) vs. Triton X-100 (0.1-0.3%)

  • Buffer composition: Include protein carrier (0.5-2% BSA) to reduce non-specific binding

• Controls framework:

  • Fluorescence-minus-one (FMO) controls for accurate gating

  • Single-stained compensation controls

  • YHR071C-A knockout samples for specificity validation

• Data analysis approach:

  • Implement density plots rather than histograms for co-expression analysis

  • Consider dimensionality reduction techniques (tSNE, UMAP) for complex datasets

  • Perform Boolean gating to identify specific cell populations

This comprehensive approach mirrors techniques used in immune profiling studies and is essential for accurate quantification of YHR071C-A in heterogeneous samples .

What are the best approaches for using YHR071C-A antibodies in quantitative protein analysis?

For accurate quantitative analysis using YHR071C-A antibodies:

• Western blot quantification:

  • Establish linear dynamic range through standard curve

  • Implement internal loading controls (housekeeping proteins)

  • Utilize fluorescent secondary antibodies for wider linear range compared to chemiluminescence

  • Analyze using digital image analysis software with background subtraction

• ELISA development:

  • Optimization matrix:

  Parameter	Range to Test	Evaluation Criteria
  Capture antibody	1-10μg/ml	Background vs. signal
  Detection antibody	0.1-2μg/ml	Signal:noise ratio
  Sample dilution	Serial 2-fold	Linearity in standard curve
  Blocking agent	BSA vs. milk vs. commercial blockers	Lowest background

  • Standard curve preparation: Recombinant YHR071C-A protein, 8-point 2-fold dilution series

  • Quantification approach: 4-parameter logistic regression fitting

• Multiplex assay approaches:

  • Bead-based assays for simultaneous measurement of YHR071C-A and interacting partners

  • Spatial analysis techniques (IF, IHC) with digital image analysis

  • Protein array applications with computational normalization

• Absolute quantification strategies:

  • Implement AQUA peptides as internal standards for mass spectrometry

  • Develop surrogate peptide standard curves for targeted proteomics

  • Consider isotope-labeled recombinant standards for Western blot calibration

These quantitative approaches parallel methodologies used in validating clinical biomarkers and allow for robust, reproducible measurement of YHR071C-A protein levels across experimental conditions .

How can YHR071C-A antibodies be utilized to study protein-protein interactions in native complexes?

For studying YHR071C-A in native protein complexes:

• Proximity-based interaction mapping:

  • BioID approach: Generate YHR071C-A-BirA* fusion for proximal protein biotinylation

  • APEX2 tagging: Create YHR071C-A-APEX2 fusion for electron microscopy-compatible labeling

  • Implementation protocol includes:

    • Expression validation with YHR071C-A antibodies

    • Biotin/substrate pulse labeling (18-24 hours for BioID, 1 minute for APEX2)

    • Streptavidin pulldown and mass spectrometry analysis

• Co-immunoprecipitation strategy:

  • Native complex preservation through:

    • Mild detergent extraction (0.1% NP-40 or Digitonin)

    • Short solubilization time (30 minutes at 4°C)

    • Physiological salt concentration (150mM NaCl)

  • Sequential immunoprecipitation:

    • First IP with YHR071C-A antibody

    • Elution under native conditions

    • Second IP with antibody against suspected interacting partner

• In situ interaction validation:

  • Proximity ligation assay (PLA) optimization:

    • Antibody concentration: 1-5μg/ml for each primary antibody

    • Proximity threshold: <40nm between epitopes

    • Controls: Single primary antibodies, non-interacting protein pairs

• Crosslinking mass spectrometry integration:

  • DSS or formaldehyde crosslinking of intact cells/organelles

  • YHR071C-A immunoprecipitation from crosslinked material

  • MS/MS analysis with crosslink-specific search algorithms

These methodologies mirror approaches used in characterizing therapeutic antibody targets and provide multi-layered evidence for protein-protein interactions involving YHR071C-A .

What strategies can be employed to develop function-blocking antibodies against YHR071C-A?

For developing function-blocking YHR071C-A antibodies:

• Epitope-focused screening strategy:

  • Structural analysis to identify functional domains/interfaces

  • Phage display library screening with counter-selection against non-functional epitopes

  • Yeast surface display evolution for increased affinity to functional sites

• Functional screening cascade:

  • Primary binding screen: Surface plasmon resonance (SPR) for epitope localization

  • Secondary cell-based screens:

    • Phenotypic reversal assays

    • Reporter gene modulation

    • Protein localization disruption

  • Tertiary mechanistic validation through:

    • Protein interaction disruption assays

    • Enzyme activity modulation tests

    • Conformational change assessment

• Antibody engineering considerations:

  • Format optimization:

    • Fab vs. scFv vs. full IgG for tissue penetration and avidity

    • Domain-specific antibodies for precise functional targeting

  • Affinity maturation strategy:

    • CDR walking for incremental improvement

    • Directed evolution under functional selection pressure

• Validation framework:

  • Dose-response characterization across multiple functional readouts

  • Comparison with genetic knockout/knockdown phenotypes

  • Competition assays with natural ligands/interactors

This approach parallels the development of therapeutic antibodies like YM101, which target specific functional domains to achieve biological effects .

How can researchers design experiments to investigate the role of post-translational modifications using YHR071C-A antibodies?

For studying post-translational modifications (PTMs) of YHR071C-A:

• Modification-specific antibody development:

  • Generate phospho-specific, acetylation-specific, or other PTM-specific antibodies

  • Validation requirements:

    • Peptide ELISA with modified vs. unmodified peptides

    • Western blot comparison before/after enzymatic removal of modification

    • IP-MS confirmation of enrichment for modified forms

• Temporal dynamics analysis:

  • Synchronization strategies for cell cycle studies

  • Stimulation time course experiments

  • Quantitative Western blot or targeted mass spectrometry

  • Digital image analysis for spatial resolution of modifications

• PTM crosstalk investigation:

  • Sequential IP approach:

    • First IP with modification-specific antibody

    • Analysis of co-occurring modifications by Western blot or MS

  Experimental Condition	Phosphorylation (pSer/pThr)	Acetylation (Ac-Lys)	Ubiquitination (Ub-Lys)
  Basal	+	+	-
  Stress-induced	+++	-	++
  Inhibitor-treated	-	+++	+

• Functional impact assessment:

  • Correlation between modification state and:

    • Protein localization (IF/IHC with modification-specific antibodies)

    • Protein-protein interactions (IP with modification-specific antibodies)

    • Protein stability (CHX chase with modification detection)

    • Enzymatic activity (activity assays after IP with modification-specific antibodies)

• Integration with genetic approaches:

  • Mutation of modification sites (phosphomimetic/non-phosphorylatable)

  • Enzyme knockout/inhibition (kinases, phosphatases, acetyltransferases)

  • Rescue experiments with wild-type vs. modification-deficient constructs

These methodological approaches mirror techniques used in characterizing therapeutic antibody targets and enable comprehensive analysis of YHR071C-A regulation through PTMs .

How can YHR071C-A antibodies be incorporated into high-throughput screening platforms?

For implementing YHR071C-A antibodies in high-throughput screens:

• Assay miniaturization strategy:

  • 384/1536-well format adaptation:

    • Optimize antibody concentration (typically 0.1-1μg/ml)

    • Reduce volumes (5-20μl) while maintaining signal:background ratio

    • Implement automated liquid handling protocols

• Detection technology selection:

  • AlphaLISA/AlphaScreen for homogeneous, no-wash detection

  • High-content imaging for subcellular resolution

  • HTRF/TR-FRET for robust, sensitive readouts with reduced interference

• Multi-parameter assay development:

  • Multiplexed readouts:

    • YHR071C-A levels/modifications

    • Downstream signaling events

    • Phenotypic consequences

  • Data integration approaches:

    • Machine learning for pattern recognition

    • Multivariate statistical analysis

• Quality control implementation:

  • Z' factor optimization (target >0.5 for robust screening)

  • Plate uniformity assessment (edge effects, drift)

  • Day-to-day reproducibility monitoring through control wells

• Screening library considerations:

  • Compound libraries targeting YHR071C-A pathways

  • Genetic perturbation libraries (CRISPR, RNAi)

  • Focused vs. diverse chemical matter

This methodological approach draws from techniques implemented in antibody discovery platforms like REAP, which enable high-throughput screening of antibody-antigen interactions .

What are the considerations for using YHR071C-A antibodies in combination with CRISPR-Cas9 genome editing?

For integrating YHR071C-A antibodies with CRISPR technologies:

• Antibody-guided validation strategy:

  • Genomic modification confirmation:

    • Western blot analysis of knockout efficiency

    • Immunofluorescence for protein depletion visualization

    • Flow cytometry for quantitative knockout assessment across cell populations

• Epitope preservation assessment:

  • For knock-in/tagging approaches:

    • Verify antibody compatibility with fusion proteins/tags

    • Test epitope accessibility in different tag configurations

    • Compare detection sensitivity between endogenous and tagged protein

• Functional interrogation design:

  • Combined antibody/CRISPR approaches:

    • Antibody-based protein detection in CRISPR-modified backgrounds

    • Rescue experiments with antibody-based functional readouts

    • Domain-specific deletions with domain-specific antibody detection

• Temporal analysis integration:

  • Inducible CRISPR systems with antibody-based kinetic monitoring

  • Degradation tag systems (AID, dTAG) with quantitative antibody detection

  • Time-resolved subcellular tracking after genetic manipulation

• Single-cell analysis approaches:

  • Multi-parameter flow cytometry combining:

    • YHR071C-A antibody detection

    • CRISPR efficiency markers

    • Functional readouts

  • High-content imaging with digital image analysis

  • CITE-seq for combined transcriptome/protein analysis

These integrated approaches parallel methodologies used in antibody target validation and enable comprehensive functional annotation of YHR071C-A .

How can researchers effectively utilize YHR071C-A antibodies in multi-omics research approaches?

For multi-omics integration with YHR071C-A antibodies:

• Proteogenomic correlation strategy:

  • Parallel analysis workflow:

    • RNA-seq for transcript levels

    • YHR071C-A antibody-based protein quantification

    • Correlation analysis between transcript and protein

  • Modification-specific antibodies to connect:

    • Phosphoproteomics data

    • Kinase activity inference

    • Signaling pathway activation states

• Spatial multi-omics integration:

  • Imaging-based multi-parameter analysis:

    • Multiplex immunofluorescence with YHR071C-A antibodies

    • Digital spatial profiling for region-specific analysis

    • Integration with spatial transcriptomics

  • Data integration approaches:

    • Cell type deconvolution

    • Spatial correlation analysis

    • Neighborhood functionality mapping

• Temporal multi-omics design:

  • Time-series experimental framework:

    • Synchronized perturbation across biological replicates

    • Parallel sampling for different omics platforms

    • YHR071C-A antibody-based anchoring of protein data

  • Analysis strategies:

    • Trajectory reconstruction

    • Temporal network modeling

    • Causal inference approaches

• Single-cell multi-omics implementation:

  • CITE-seq/REAP-seq adaptation for YHR071C-A:

    • Oligonucleotide-conjugated YHR071C-A antibodies

    • Capture protocol optimization

    • Computational integration with transcriptome

• Functional multi-omics correlation:

  • YHR071C-A perturbation with multi-level phenotyping:

    • Antibody-based protein quantification

    • Transcriptome profiling

    • Metabolomic/lipidomic analysis

    • Functional readouts (proliferation, migration, etc.)

These multi-omics approaches draw from techniques implemented in high-throughput characterization platforms and enable comprehensive understanding of YHR071C-A function in complex biological systems .